Market Overview:
The global venlafaxine hydrochloride market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of depression and anxiety disorders, rising geriatric population, and growing demand for venlafaxine hydrochloride in emerging markets. However, the high cost of treatment and side effects associated with venlafaxine hydrochloride are expected to restrain the growth of this market during the forecast period. The global venlafaxine hydrochloride market is segmented on the basis of type, application, and region. On the basis of type, it is divided into more than or equal to 98%, < 98%. On the basis of application, it is classified into tablet form (oral), capsule form (oral), other forms (injectable). The tablet form accounted for a major share in 2017 owing to its easy availability and low cost as compared to other forms. Geographically, it is analyzed across North America (U.S., Canada), Latin America (Brazil Mexico), Europe(Germany France Italy Spain U K.), Asia Pacific(China Japan India South Korea Australia New Zealand) Middle East & Africa(GCC Countries Turkey Iran South Africa).
Product Definition:
Venlafaxine Hydrochloride is a drug that is used to treat depression, anxiety, and panic disorders. It is in a class of drugs called serotonin and norepinephrine reuptake inhibitors (SNRIs). Venlafaxine Hydrochloride helps to increase the levels of serotonin and norepinephrine in the brain. This medication is important because it can help people who have depression or anxiety disorders to improve their moods and feel better.
More than or euqal to 98%:
The more than or euqal to 98% claim refers to the situation where a single source of raw material is available and can be used for the production of different products. In such situations, it is possible to produce more than or euqally (two sources) enough product for the required quantity with no wastage. This phenomenon holds good particularly in case of Venlafaxine Hydrochloride, which can be produced from two sources i.e.
< 98%:
The FDA has set the upper limit for normal blood pressure levels at 130/85 mm Hg. If your readings are between 120/80 and 129/86 mm Hg, then it is considered as high normal blood pressure level. Similarly, if your readings are between 110/75 and 119/82 mm Hg, then it is considered as low normal blood pressure level.
According to the American Heart Association (AHA), about 37 million people in U.
Application Insights:
Based on the application, the global venlafaxine hydrochloride market is segmented into tablet, capsule and others. The tablet was estimated as largest revenue-generating segment in 2017. Venlafaxine is an oral antidepressant which has been used for decades to treat depression and other mental illnesses. It works by affecting the reuptake of serotonin in the brain; thus increasing its levels there leading to improved mental health.
The growing prevalence of depression across all age groups coupled with rising awareness about treatment options is expected to boost product demand over the forecast period. In addition, growing usage of venlafaxine for treating obesity coupled with a high success rate associated with this drug are some factors that may drive market growth over next few years.
Regional Analysis:
Europe was the largest market for venlafaxine hydrochloride, accounting for more than 35.0% of global revenue in 2017. The presence of key manufacturers coupled with a well-established healthcare infrastructure is expected to remain a favorable factor over the forecast period.
Asia Pacific is anticipated to be one of the fastest growing regions owing to increasing disposable income levels and rising demand from emerging countries such as China and India which have been experiencing strong economic growths in recent years.
Growth Factors:
- Increasing prevalence of depression and anxiety disorders
- Growing awareness about the benefits of venlafaxine hydrochloride therapy
- Rising demand for better-tolerated antidepressants with fewer side effects
- Availability of generic versions of venlafaxine hydrochloride drugs
- Technological advancements in drug delivery systems
Scope Of The Report
Report Attributes
Report Details
Report Title
Venlafaxine Hydrochloride Market Research Report
By Type
More than or euqal to 98%, < 98%
By Application
Tablet, Capsule, Other
By Companies
Pfizer, Mesha Pharma, Sun Pharmaceutical Industries, Taj API, Synergy Pharmaceutical, Winsunny Harmony Science & Technology, Suzhou No.4 Pharmaceutical Factory
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
250
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Venlafaxine Hydrochloride Market Report Segments:
The global Venlafaxine Hydrochloride market is segmented on the basis of:
Types
More than or euqal to 98%, < 98%
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Tablet, Capsule, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Mesha Pharma
- Sun Pharmaceutical Industries
- Taj API
- Synergy Pharmaceutical
- Winsunny Harmony Science & Technology
- Suzhou No.4 Pharmaceutical Factory
Highlights of The Venlafaxine Hydrochloride Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- More than or euqal to 98%
- < 98%
- By Application:
- Tablet
- Capsule
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Venlafaxine Hydrochloride Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Venlafaxine hydrochloride is a medication used to treat depression. It works by increasing the levels of serotonin in the brain.
Some of the major companies in the venlafaxine hydrochloride market are Pfizer, Mesha Pharma, Sun Pharmaceutical Industries, Taj API, Synergy Pharmaceutical, Winsunny Harmony Science & Technology, Suzhou No.4 Pharmaceutical Factory.
The venlafaxine hydrochloride market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Venlafaxine Hydrochloride Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Venlafaxine Hydrochloride Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Venlafaxine Hydrochloride Market - Supply Chain
4.5. Global Venlafaxine Hydrochloride Market Forecast
4.5.1. Venlafaxine Hydrochloride Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Venlafaxine Hydrochloride Market Size (000 Units) and Y-o-Y Growth
4.5.3. Venlafaxine Hydrochloride Market Absolute $ Opportunity
5. Global Venlafaxine Hydrochloride Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Venlafaxine Hydrochloride Market Size and Volume Forecast by Type
5.3.1. More than or euqal to 98%
5.3.2. < 98%
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Venlafaxine Hydrochloride Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Venlafaxine Hydrochloride Market Size and Volume Forecast by Application
6.3.1. Tablet
6.3.2. Capsule
6.3.3. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Venlafaxine Hydrochloride Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Venlafaxine Hydrochloride Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Venlafaxine Hydrochloride Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Venlafaxine Hydrochloride Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Venlafaxine Hydrochloride Demand Share Forecast, 2019-2026
9. North America Venlafaxine Hydrochloride Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Venlafaxine Hydrochloride Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Venlafaxine Hydrochloride Market Size and Volume Forecast by Application
9.4.1. Tablet
9.4.2. Capsule
9.4.3. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Venlafaxine Hydrochloride Market Size and Volume Forecast by Type
9.7.1. More than or euqal to 98%
9.7.2. < 98%
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Venlafaxine Hydrochloride Demand Share Forecast, 2019-2026
10. Latin America Venlafaxine Hydrochloride Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Venlafaxine Hydrochloride Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Venlafaxine Hydrochloride Market Size and Volume Forecast by Application
10.4.1. Tablet
10.4.2. Capsule
10.4.3. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Venlafaxine Hydrochloride Market Size and Volume Forecast by Type
10.7.1. More than or euqal to 98%
10.7.2. < 98%
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Venlafaxine Hydrochloride Demand Share Forecast, 2019-2026
11. Europe Venlafaxine Hydrochloride Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Venlafaxine Hydrochloride Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Venlafaxine Hydrochloride Market Size and Volume Forecast by Application
11.4.1. Tablet
11.4.2. Capsule
11.4.3. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Venlafaxine Hydrochloride Market Size and Volume Forecast by Type
11.7.1. More than or euqal to 98%
11.7.2. < 98%
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Maket Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Venlafaxine Hydrochloride Demand Share, 2019-2026
12. Asia Pacific Venlafaxine Hydrochloride Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Venlafaxine Hydrochloride Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Venlafaxine Hydrochloride Market Size and Volume Forecast by Application
12.4.1. Tablet
12.4.2. Capsule
12.4.3. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Venlafaxine Hydrochloride Market Size and Volume Forecast by Type
12.7.1. More than or euqal to 98%
12.7.2. < 98%
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Venlafaxine Hydrochloride Demand Share, 2019-2026
13. Middle East & Africa Venlafaxine Hydrochloride Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Venlafaxine Hydrochloride Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Venlafaxine Hydrochloride Market Size and Volume Forecast by Application
13.4.1. Tablet
13.4.2. Capsule
13.4.3. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Venlafaxine Hydrochloride Market Size and Volume Forecast by Type
13.7.1. More than or euqal to 98%
13.7.2. < 98%
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Venlafaxine Hydrochloride Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Venlafaxine Hydrochloride Market: Market Share Analysis
14.2. Venlafaxine Hydrochloride Distributors and Customers
14.3. Venlafaxine Hydrochloride Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Pfizer
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Mesha Pharma
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Sun Pharmaceutical Industries
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Taj API
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Synergy Pharmaceutical
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Winsunny Harmony Science & Technology
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Suzhou No.4 Pharmaceutical Factory
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook